Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- MARI.VI
- Price
- 19.00
- Stock movement up
- +- (0.00%)
- Company name
- Marinomed Biotech AG
- Exchange
- (VI ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 34.96M
- Ent value
- 46.55M
- Price/Sales
- 7.99
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 12.75
- PEG
- -
- EPS growth
- 12.04%
- 1 year return (CAGR)
- 32.87%
- 3 year return (CAGR)
- -29.14%
- 5 year return (CAGR)
- -30.71%
- 10 year return (CAGR)
- -
Last updated: 2026-02-13
DIVIDENDS
MARI.VI does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 7.99 |
| Price to Book | - |
| EV to Sales | 10.64 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.84M |
| EPS (TTM) | -6.91 |
| FCF per share (TTM) | -1.87 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 4.37M |
| Gross profit (TTM) | 1.02M |
| Operating income (TTM) | -4.97M |
| Net income (TTM) | -12.29M |
| EPS (TTM) | -6.91 |
| EPS (1y forward) | 1.49 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 23.34% |
| Operating margin (TTM) | -113.61% |
| Profit margin (TTM) | -280.93% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.49M |
| Net receivables | 502.99K |
| Total current assets | 2.98M |
| Goodwill | 0.00 |
| Intangible assets | 16.68K |
| Property, plant and equipment | 4.64M |
| Total assets | 7.64M |
| Accounts payable | 283.53K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 5.10M |
| Total liabilities | 13.08M |
| Shareholder's equity | -5.44M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -3.32M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -3.32M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -160.77% |
| Return on Invested Capital | -620.88% |
| Cash Return on Invested Capital | -167.76% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 19.00 |
| Daily high | 19.00 |
| Daily low | 19.00 |
| Daily Volume | 0K |
| All-time high | 145.00 |
| 1y analyst estimate | 50.50 |
| Beta | -0.28 |
| EPS (TTM) | -6.91 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| MARI.VI | S&P500 | |
| Current price drop from All-time high | -86.90% | -1.40% |
| Highest price drop | -96.66% | -56.47% |
| Date of highest drop | 22 Aug 2024 | 9 Mar 2009 |
| Avg drop from high | -48.38% | -10.86% |
| Avg time to new high | 32 days | 12 days |
| Max time to new high | 1235 days | 1805 days |
COMPANY DETAILS
Marketcap
34.96M
Marketcap category
Small-cap
Description
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. It operates through Virology, Immunology, and Other segments. The company's products pipeline includes Budesolv for the treatment of allergic rhinitis; Tacrosolv, which is in Phase II clinical trial for inflammatory eye diseases; and Inhaleen for viral infection of the upper and lower respiratory tract. It also provides Solv4U which offers formulation development and biopharmaceutical testing services. It has a technology partnership with SPH Sine Pharmaceutical Laboratories Co. Ltd. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.
Employees
33
Website
Investor relations
-
SEC filings
CEO
Country
Austria
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Amidst concerns over the independence of the U.S. Federal Reserve and renewed tariff uncertainties, European markets have been experiencing a downturn, with major indices such as the STOXX Europe 600 ...
September 3, 2025
Amidst the backdrop of economic uncertainties and geopolitical tensions, European markets have recently experienced a downturn, with major indices like the STOXX Europe 600 Index closing lower. In suc...
September 2, 2025
As European markets grapple with concerns over U.S. Federal Reserve independence, renewed tariff uncertainties, and political instability, the pan-European STOXX Europe 600 Index recently ended 1.99% ...
September 2, 2025
As European markets face challenges from political instability and economic uncertainties, the pan-European STOXX Europe 600 Index recently experienced a decline of nearly 2%. In such a climate, growt...
September 1, 2025
As European markets experience a positive shift, buoyed by hopes of lower U.S. borrowing costs and an uptick in business activity, investors are increasingly focusing on growth companies with strong i...
August 29, 2025
As European markets experience a lift from the prospect of lower U.S. borrowing costs, with indices like the STOXX Europe 600 and UK’s FTSE 100 reaching new highs, investors are increasingly keen on i...
August 29, 2025
As the European markets experience a modest uplift, buoyed by expectations of lower U.S. borrowing costs and a rebound in manufacturing activity, investors are increasingly turning their attention to ...
August 28, 2025
As European markets experience a lift from the prospect of lower U.S. borrowing costs, with most major stock indexes rising and the UK’s FTSE 100 Index reaching record highs, investors are increasingl...
August 28, 2025
As European markets experience a boost from hopes of lower U.S. borrowing costs, with the pan-European STOXX Europe 600 Index rising by 1.40%, investors are increasingly interested in growth stocks th...
August 27, 2025
As European markets experience a lift, buoyed by the prospect of lower U.S. borrowing costs, major indices like the STOXX Europe 600 and the UK's FTSE 100 have shown positive momentum. In this environ...
August 27, 2025
Next page